Trial intelligence / Profile preview

MOTION phase 3 trial of vimseltinib in tenosynovial giant cell tumor

NL-OMON56439Phase 3Active, not recruiting

Sponsor

Deciphera Pharmaceuticals

Start

Mar 2022

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1